Omar On, PA
Physician Assistant · Chico, CANPI 1295889871
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Incyte Corporation at 48.9% of the total. Reporting peaked in 2022 at $20,034 and has fallen 88.5% since, to $2,295 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,071 payments — averaging $59.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$31K
- Sun Pharmaceutical Industries Inc.$13K
- AbbVie$8K
- Johnson & Johnson$2K
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $8K from 26 others
What the payments were for
- Consulting fees$2,2023%
- Speaking & faculty fees$32,60051%
- Travel & lodging$10,26316%
- Food & beverage$17,70428%
- Education$6811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 127 | $31,018 |
| Sun Pharmaceutical Industries Inc. | 155 | $13,082 |
| AbbVie | 192 | $7,675 |
| Johnson & Johnson | 106 | $1,691 |
| Amgen | 72 | $1,232 |
| E.r. Squibb & Sons, L.L.C. | 36 | $1,103 |
| Lilly USA, LLC | 50 | $926 |
| Sanofi | 39 | $873 |
| Pfizer | 52 | $748 |
| Verrica Pharmaceuticals Inc. | 1 | $650 |
| UCB, Inc. | 30 | $640 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 32 | $622 |
| Regeneron Healthcare Solutions, Inc. | 30 | $597 |
| Dermavant Sciences, Inc. | 29 | $453 |
| Arcutis Biotherapeutics, Inc. | 25 | $362 |
| LEO Pharma Inc. | 19 | $338 |
| Organon | 15 | $276 |
| Galderma Laboratories, L.p. | 15 | $250 |
| Novartis | 7 | $149 |
| EPI Health, LLC | 8 | $141 |
| Almirall LLC | 8 | $113 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| VYNE Pharmaceuticals Inc. | 3 | $61 |
| Botanix SB Inc | 4 | $61 |
| Biofrontera Inc. | 3 | $58 |
| Paratek Pharmaceuticals, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $53 |
| Mayne Pharma Commercial LLC | 3 | $51 |
| Organogenesis Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Strata Skin Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,449 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $242,237 |
| OtezlaApremilast | 24 | $145,201 |
| Humira(Cf) PenAdalimumab | 23 | $145,072 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 18 | $14,910 |
| Clobetasol Propionate | 112 | $6,003 |
| Metronidazole | 55 | $5,158 |
| Doxycycline Hyclate | 109 | $2,963 |
| ValacyclovirValacyclovir Hcl | 46 | $2,514 |
| Fluorouracil | 38 | $2,450 |
| Triamcinolone Acetonide | 194 | $2,377 |
| Ketoconazole | 102 | $2,235 |
| Spironolactone | 103 | $1,909 |
| Fluticasone Propionate | 38 | $942 |
| Mometasone Furoate | 52 | $941 |
| Clindamycin Phosphate | 26 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,232 | $145,20124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Chico
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
- Asma HussainiThousand Oaks$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.